CGRP-targeted antibodies in difficult-to-treat migraine

被引：13
作者：
de Vries, Tessa [1 ]
MaassenVanDenBrink, Antoinette [1 ]
机构：
[1] Erasmus MC, Erasmus MC, Dept Internal Med, Rotterdam, Netherlands
来源：
NATURE REVIEWS NEUROLOGY | 2019年 / 15卷 / 12期
关键词：
D O I：
10.1038/s41582-019-0275-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A new study shows that the monoclonal antibody fremanezumab is effective for migraine prophylaxis, even in patients who have failed to respond to multiple preventive treatments. However, not all patients benefit from this treatment, and detailed investigation of non-responders could help to identify additional pharmacological targets and increase the number of responders.
引用
收藏
页码：688 / 689
页数：2
相关论文
共 10 条
  • [1] Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
    Ashina, Messoud
    Tepper, Stewart
    Brandes, Jan Lewis
    Reuter, Uwe
    Boudreau, Guy
    Dolezil, David
    Cheng, Sunfa
    Zhang, Feng
    Lenz, Robert
    Klatt, Jan
    Mikol, Daniel D.
    [J]. CEPHALALGIA, 2018, 38 (10) : 1611 - 1621
  • [2] A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
    Depre, Christophe
    Antalik, Lubomir
    Starling, Amaal
    Koren, Michael
    Eisele, Osaro
    Lenz, Robert A.
    Mikol, Daniel D.
    [J]. HEADACHE, 2018, 58 (05): : 715 - 723
  • [3] Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
    Dodick, David W.
    Silberstein, Stephen D.
    Bigal, Marcelo E.
    Yeung, Paul P.
    Goadsby, Peter J.
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (19): : 1999 - 2008
  • [4] Basic mechanisms of migraine and its acute treatment
    Edvinsson, Lars
    Villalon, Carlos M.
    MaassenVanDenBrink, Antoinette
    [J]. PHARMACOLOGY & THERAPEUTICS, 2012, 136 (03) : 319 - 333
  • [5] Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
    Ferrari, Michel D.
    Diener, Hans Christoph
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    Mueller, Matthias
    Ahn, Andrew H.
    Schwartz, Yael Carmeli
    Grozinski-Wolff, Melissa
    Janka, Lindsay
    Ashina, Messoud
    [J]. LANCET, 2019, 394 (10203) : 1030 - 1040
  • [6] Wiping Out CGRP: Potential Cardiovascular Risks
    MaassenVanDenBrink, Antoinette
    Meijer, Joris
    Villalon, Carlos M.
    Ferrari, Michel D.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (09) : 779 - 788
  • [7] Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
    Reuter, Uwe
    Goadsby, Peter J.
    Lanteri-Minet, Michel
    Wen, Shihua
    Hours-Zesiger, Peggy
    Ferrari, Michel D.
    Klatt, Jan
    [J]. LANCET, 2018, 392 (10161) : 2280 - 2287
  • [8] European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
    Sacco, Simona
    Bendtsen, Lars
    Ashina, Messoud
    Reuter, Uwe
    Terwindt, Gisela
    Mitsikostas, Dimos-Dimitrios
    Martelletti, Paolo
    [J]. JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1)
  • [9] Fremanezumab for the Preventive Treatment of Chronic Migraine
    Silberstein, Stephen D.
    Dodick, David W.
    Bigal, Marcelo E.
    Yeung, Paul P.
    Goadsby, Peter J.
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    Aycardi, Ernesto
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22) : 2113 - 2122
  • [10] Is CGRP Receptor Blockade Cardiovascularly Safe? Appropriate Studies Are Needed
    van den Brink, A. Maassen
    Rubio-Beltran, E.
    Duncker, D.
    Villalon, C. M.
    [J]. HEADACHE, 2018, 58 (08): : 1257 - 1258
1